



UniversitätsKlinikum Heidelberg



Program

Translations in Urologic Oncology

January 25th-26th, 2013

German Cancer Research Center (DKFZ),
Communication Center, Heidelberg

www.uro-oncology2013.com



Introduction

Dear colleagues,

Not long ago, the mantra was that science, like history, repeats itself. One of the major contributing facts to this phenomenon was that clinicians started all over again discovering evidence, which previously had been revealed by basic researchers already.

The advent of ‘translational medicine’, however, represents a fundamentally new aspect where the formerly independent ‘galaxies’ of basic and clinical science find to each other on a fast-track. This involves not only the classical ‘bench-to-bedside’ approach but also increasingly research strategies ‘bedside-to-bench’, which likewise turn out to be extremely fruitful. Additionally, a still much neglected aspect of translational science is the exchange of knowledge between researchers, who focus on different entities that still may share common pathological and curative pathways like for example leukemia and renal cell cancer.

The public audience expects, given the investments made, transformative patient care to be implemented as fast as possible. Only the free exchange of knowledge between researchers from different ‘worlds’ such as engineering, computational biology or chemistry and medicine will help to develop new solutions for common health care problems.

Ideally, ‘translational science’ functions like a neuronal network in it’s every sense that it produces, collects, organizes and presents evidence with all possible scientific and clinical parties involved. The costs of implementing such infrastructures may appear overwhelming. However, currently a floodwave of new and extremely expensive therapies is finding its way into clinical routine, where many of the drugs are effective overall - but sometimes in an unpredictable way in the individual patient. Therefore, sophisticated translational medicine with its potential to develop into personalized medicine will be the only solution for the future, which will be characterized by high expectations in terms of cure rates and economical limitations at the same time.

The symposium »Translations in Urologic Oncology« brings together some of the most eminent people in the field from around the world. It aims to explore today’s frontiers of treatment of tumors that account for approximately twenty-five percent of all malignancies: urological cancers.

Advances in *silico* as well as imaging, individualized next generation sequencing and tumor profiling, biomarkers, cancer stem cells and immunotherapy as well as current progress in local and systemic therapies will be highlighted. In addition, general aspects of ‘doing science’ such as the more and more urgent pressure to publish and to find the funds that are needed to move the science forward will be discussed.

We cordially welcome you in Heidelberg.

Best regards, on behalf of the organizing committee,

Boris Hadaschik, Sascha Pahernik, Markus Hohenfellner
UniversityHospital Heidelberg

Come together at the Social Event Kulturbrauerei Heidelberg



When: Friday 25th of January, 2013, 19:30

Where: Kulturbrauerei Heidelberg
Leyergasse 6
69117 Heidelberg

For transportation services, ask at the Registration Desk.



- Brewery, restaurant and hotel in the middle of the historic part of Heidelberg
- Ancient student tavern with traditional interior
- Long Brewery tradition dating back to 1235

Program Friday 25th January, 2013

Welcome address I

13:00 Markus Hohenfellner, UniversityHospital Heidelberg

Welcome address II

Guido Adler, UniversityHospital Heidelberg , Heidelberg

Key note lecture

13:15 **From idea to global use**
Harald zur Hausen, DKFZ, Heidelberg

Advances *in vitro* and *in silico*

Chairs: Gedske Daugaard, Copenhagen; Norbert Graf, Homburg;
Oliver Hakenberg, Rostock; Christoph Zielinski, Wien

14:00 **The 1000 Genomes Project Consortium**
Jan Korbel, EMBL, Heidelberg

14:30 **What can we learn from the translation of genome analyses in leukemia to common tumors in urology?**
Andreas Kulozik, UniversityHospital Heidelberg

15:00 **Genome sequences and next-generation classification of prostate cancer**
Holger Sultmann, NCT, Heidelberg

15:30 **State of the art – biomarkers**
Ronald DePinho, MDACC, Houston

16:15 **Discussion, coffee break**

Individual profiling of tumors – the future in drug development and multidisciplinary cancer treatment

Chairs: Markus Elsner, New York; Estrid Hogdall, Copenhagen;
Martina Müller-Schilling, Regensburg

17:10 **The preclinical perspective**
Stefan Duensing, UniversityHospital Heidelberg

17:30 **The clinical trialist's perspective**
Cora Sternberg, San Camillo and Forlanini Hospitals, Rom

17:50 **The NCT perspective on personalized diagnosis and treatment of cancer**
Christof von Kalle, NCT, Heidelberg

18:10 **Personalized medicine: economic hype or true progress?**
Volker Diehl, Cologne University Hospital, Köln

18:30 **Round table discussion**

Social Event

19:30 **Come together at the „Kulturbrauerei“**

Program Saturday 26th January, 2013

Imaging advances

Chairs: Abdulla Al Ansari, Doha; Michael Flentje, Würzburg;
Axel Haferkamp, Frankfurt; Wolf Wieland, Regensburg

08:30 **Urogenital MR-Imaging: the more Tesla the better?**
Heinz-Peter Schlemmer, DKFZ, Heidelberg

08:50 **At the forefront of radiopharmaceuticals**
Uwe Haberkorn, UniversityHospital Heidelberg

09:10 **State of the art – molecular imaging in urological tumors**
Hedvig Hricak, MSKCC, New York

09:40 **Discussion, coffee break**

Perspectives in local and systemic therapy

Chairs: Vito Pansadoro, Rom; Jacob Ramon, Tel Aviv; Jens Rassweiler, Heilbronn;
Levent Türkeri, Istanbul; Xu Zhang, Peking

10:30 **Navigating towards augmented reality**
Dogu Teber, Sascha Pahernik (UniversityHospital Heidelberg)
and Hans-Peter Meinzer (DKFZ, Heidelberg)

10:50 **Heavy ion therapy – software guiding hardware for treatment**
Jürgen Debus, UniversityHospital Heidelberg

11:10 **Targeted therapy in pediatric urooncology**
Hedwig Deubzer, DKFZ, Heidelberg

11:30 **State of the art – cancer stem cells and metastasis initiating cells**
Andreas Trumpp, DKFZ, Heidelberg

12:00 **Round table discussion, lunch break**

Applied Translations

Chairs: Maria De Santis, Wien; Michael Droller, New York; Glen Kristiansen, Bonn;
Stefan Müller, Bonn; Michael Stöckle, Homburg

13:30 **Cancer research from bench to bedside: challenges for urologic oncology**
Otmar Wiestler, DKFZ, Heidelberg

14:00 **The future of surgery: lost in translation?**
Markus Hohenfellner, Boris Hadaschik, UniversityHospital Heidelberg

14:30 **From phase 2 in clinical routine:
the success story of cisplatin chemotherapy**
Peter Albers, Düsseldorf University Hospital

Program Saturday 26th January, 2013

15:00 **Translational research – the publisher's perspective**
Markus Elsner, Nature Biotechnology, New York

15:30 **Locally advanced and node positive prostate cancer –
progress through international co-operation**
Fritz Schroeder, Erasmus University and Academic Hospital, Rotterdam

16:00 **Discussion, coffee break**

Immunotherapy

Chairs: Alessandro Bertaccini, Bologna; Arndt Hartmann, Erlangen; Elke Jäger, Frankfurt;
Helmut Klocker, Innsbruck; Bernd Wullich, Erlangen; Martin Zeier, Heidelberg

17:00 **Tumor biology and vaccine development**
Magnus von Knebel Doeberitz, UniversityHospital Heidelberg

17:30 **Future of cellular immunotherapy**
Charles Drake, Johns Hopkins SKCCC, Baltimore

18:00 **Modulating the tumor micromilieu**
Dirk Jäger, NCT, Heidelberg

18:30 **Discussion, farewell**

Scientific Board



Jürgen Debus

Institution: UniversityHospital Heidelberg

is Professor of Radiotherapy at the University of Heidelberg and Director of the Department of Radiation Oncology. Since 1997, he is Chair of the German Heavy Ion Radiotherapy Project. His main interests lie in the development of heavy ion therapy and precision radiotherapy to improve patient outcomes.



Stefan Duensing

Institution: UniversityHospital Heidelberg

is Head of the Section of Molecular Urooncology of the Department of Urology of the University of Heidelberg. His work focuses on genomic instability in cancer and novel ways to detect, treat and prevent prostate and renal cancer.



Markus Hohenfellner

Institution: UniversityHospital Heidelberg

is Professor of Urology and Director of the Dept. of Urology of the UniversityHospital Heidelberg. His main activities are uro-oncology including minimally invasive, robotic, ultraradical and reconstructive surgery as well as multimodular interdisciplinary comprehensive cancer therapy. Within the German Cancer Aid Foundation he is specially focused on »novel tools« in oncology and biobanking.



Dirk Jäger

Institution: NCT, Heidelberg

is Head of the Dept. of Medical Oncology and Member of the Board of Directors of the NCT in Heidelberg. His main interest lies in immunotherapy of cancer using antibody based approaches, T cell based approaches and different strategies of immunomodulation.



Andreas Kulozik

Institution: UniversityHospital Heidelberg

is Professor of Pediatrics and Director of the Dept. of Pediatric Oncology of the UniversityHospital Heidelberg. He is interested in personalized treatment approaches in pediatric leukemia and discovered actionable risk markers in precursor T-lymphoblastic leukemia. On a more basic level, he discovered mechanisms of regulated mRNA stability and 3'end mRNA processing.

Scientific Board



Heinz-Peter Schlemmer

Institution: DKFZ, Heidelberg

is Head of the Dept. of Radiology at the DKFZ. As both a physicist and physician he is an expert for developing imaging methods for early detection of cancer and characterizing its functional and biologic features. He develops new techniques for ultra-high field MRI and dual-energy CT and PET/CT.



Holger Sültmann

Institution: DKFZ, Heidelberg

is Head of the Cancer Genome Research Unit of the Structural and Functional Genomics Facility at the DKFZ. He is Coordinator and Head of the Integrated Genome Research Project Prostate Cancer as part of the International Cancer Genome Consortium.



Christof von Kalle

Institution: NCT and DKFZ, Heidelberg

is Head of the Dept. of Translational Oncology at the NCT and the DKFZ. He chairs the NCT Board of Directors. He is Chair of the comprehensive cancer center network of the German Cancer Aid. His main research fields are stem cell research, mutation analyses and gene transfer.

Speakers



Guido Adler

Institution: UniversityHospital Heidelberg

is Medical Director and Chairman of the Board of the University Hospital Heidelberg. He is a leader in the field of Medicine and Gastroenterology and Chairman of the Health Research Board of the German Federal Ministry of Education and Research and a Member of the Austrian Science Board.



Peter Albers

Institution: Düsseldorf University Hospital

is Professor and Chairman of the Department of Urology at the University of Düsseldorf, Düsseldorf, Germany. He is an expert in the field of uro-oncology and as such Member of the European Organisation for the Research and Treatment of Cancer (EORTC) GU Group and Chairman of the European Association of Urology (EAU) Testis Cancer Guidelines Group. He is Past Congress President of the German Cancer Congress and was recently elected as Vice Chairman of the German Cancer Society.



Jürgen Debus

Institution: UniversityHospital Heidelberg

is Professor of Radiotherapy at the University of Heidelberg and Director of the Department of Radiation Oncology. Since 1997, he is Chair of the German Heavy Ion Radiotherapy Project. His main interests lie in the development of heavy ion therapy and precision radiotherapy to improve patient outcomes.



Ronald DePinho

Institution: MDACC, Houston

is President of the MD Anderson Cancer Center in Houston, TX, USA. He is an internationally recognized leader in basic and translational cancer research, aging and age-associated degenerative disorders as well as in stem cell research. Dr. DePinho's independent scientific career began at Albert Einstein College of Medicine, where he established the first NCI-supported transgenic and gene targeting facility.



Hedwig Deubzer

Institution: DKFZ, Heidelberg

is Group Leader within the Clinical Cooperation Unit Pediatric Oncology of the DKFZ. Her main interest is the investigation of targeted therapies against neuroblastoma. Her research group is working on epigenetic regulations and the master regulators in neuroblastoma biology.

Speakers



Volker Diehl

Institution: University Hospital of Cologne

is Director emeritus of the Department of Medicine of the University of Cologne, Germany. He founded the German Hodgkin Study Group, which became and is one of the leading study groups for Hodgkin Disease around the globe, improving the life of thousands of patients. He was the first Director of the NCT in Heidelberg 2004-2005, implementing infrastructure and routines that carry on until today.



Charles Drake

Institution: Johns Hopkins SKCCC, Baltimore

is Assistant Professor of Oncology, Immunology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland. He is an expert for immunotherapy and recently presented the clinical usage of a specific inhibitor of T-cells against advanced prostate cancer.



Stefan Duensing

Institution: UniversityHospital Heidelberg

is Head of the Section of Molecular Urooncology of the Department of Urology of the University of Heidelberg. His work focuses on genomic instability in cancer and novel ways to detect, treat and prevent prostate and renal cancer.



Markus Elsner

Institution: Nature Biotechnology, New York

is an Associate Editor of Nature Biotechnology. With a 2011 impact factor of 23.268 Nature Biotechnology places first among the primary research journals in the field of biotechnology. He did his graduate work at EMBL in Heidelberg, and the University of Gothenburg, Sweden, where he worked on characterizing protein dynamics in living cells. In his postdoctoral studies at the NIH he investigated the mechanisms of lipid and protein sorting during membrane transport events.



Uwe Haberkorn

Institution: UniversityHospital Heidelberg

is Head of the Dept. of Nuclear Medicine at the University Heidelberg and Head of the Clinical Cooperation Unit Nuclear Medicine at the DKFZ. His science focuses on PET-imaging, identification of new peptides with high affinity for tumor disease and the establishment of new endoradiotherapy approaches based on peptides and antibodies.

Speakers



Boris Hadaschik

Institution: UniversityHospital Heidelberg


is Associate Professor at the Dept. of Urology, UniversityHospital Heidelberg. He obtained the Maximilian-Nitze-Prize for his work regarding novel intravesical agents and an orthotopic mouse model for bladder cancer. His current research focuses on prostate cancer including the development of image-guided prostate biopsy strategies and their implementation in international study groups as well as clinical trials for castration-resistant disease.



Markus Hohenfellner

Institution: UniversityHospital Heidelberg

is Professor of Urology and Director of the Dept. of Urology of the UniversityHospital Heidelberg. His main activities are uro-oncology including minimally invasive, robotic, ultraradical and reconstructive surgery as well as multimodular interdisciplinary comprehensive cancer therapy. Within the German Cancer Aid Foundation he is specially focused on »novel tools« in oncology and biobanking.



Hedvig Hricak

Institution: MSKCC, New York

is Chairman of the Dept. of Radiology at the Memorial Sloan-Kettering Cancer Center, New York. She is one of the most renowned American radiologists. She is Professor of Radiology at the Weill Medical College of Cornell University and investigates imaging methods for cancer detection and staging.



Dirk Jäger

Institution: NCT, Heidelberg

is Head of the Dept. of Medical Oncology and Member of the Board of Directors of the NCT in Heidelberg. His main interest lies in immunotherapy of cancer using antibody based approaches, T cell based approaches and different strategies of immunomodulation.



Jan Korbel

Institution: EMBL Heidelberg

is Group Leader at the EMBL. His lab studies the impact of genetic variants (SVs). In developing next-generation cancer genomics they decipher the impact of SVs in diseases. They discovered chromothripsis as an event, in which SVs are crucial for the development of childhood medulloblastoma.

Speakers



Andreas Kulozik

Institution: UniversityHospital Heidelberg

is Professor of Pediatrics and Director of the Dept. of Pediatric Oncology of the UniversityHospital Heidelberg. He is interested in personalized treatment approaches in pediatric leukemia and discovered actionable risk markers in precursor T-lymphoblastic leukemia. On a more basic level, he discovered mechanisms of regulated mRNA stability and 3'end mRNA processing.



Hans-Peter Meinzer

Institution: NCT, Heidelberg

is Head of the Division of Medical and Biological Informatics at the DKFZ. His research aims at improving diagnostic methods and treatment planning based on CT, MRI and ultrasound. Preoperative and intraoperative imaging as well as surgical navigation are his major scientific topics.



Sascha Pahernik

Institution: UniversityHospital Heidelberg

is Associate Professor at the Dept. of Urology of the UniversityHospital Heidelberg. His research focuses on surgical and medical treatment of renal cell carcinoma and the clinical development of focal ablative therapies such as HIFU for prostate cancer. He is member of the scientific council of the Else Kröner Fresenius Stiftung.



Heinz-Peter Schlemmer

Institution: DKFZ, Heidelberg

is Head of the Dept. of Radiology at the DKFZ. As both a physicist and physician he is an expert for developing imaging methods for early detection of cancer and characterizing its functional and biologic features. He develops new techniques for ultra-high field MRI and dual-energy CT and PET/CT.



Fritz Schröder

Institution: Erasmus University and Academic Hospital, Rotterdam

is past Chairman of the Department of Urology, Erasmus MC, the Netherlands. He is a clinical expert for prostate cancer and the international coordinator of the ERSPC, a prospective study that randomized 162,000 men across Europe to prove that PSA screening can indeed reduce the mortality of prostate cancer.

Speakers



Cora Sternberg

Institution: San Camillo and Forlanini Hospitals, Rom

is Head of the Dept. of Medical Oncology at the San Camillo and Forlanini Hospitals in Rome and an internationally recognized leader in uro-oncology. She pioneered the MVAC treatment regime against bladder cancer during her time at the MSKCC in New York. Today she is involved in the work of the EORTC, especially in the Genito-Urinary Cancers Group and greatly contributes to the development of clinical trials.



Holger Sültmann

Institution: DKFZ, Heidelberg

is Head of the Cancer Genome Research Unit of the Structural and Functional Genomics Facility at the DKFZ. He is Coordinator and Head of the Integrated Genome Research Project Prostate Cancer as part of the International Cancer Genome Consortium.



Dogu Teber

Institution: UniversityHospital Heidelberg

is Senior Physician at the Dept. of Urology UniversityHospital Heidelberg. His special affiliation is in the field of minimally invasive urological surgery. His main research interests lie in intraoperative navigation and in new technologies in urological imaging.



Andreas Trumpp

Institution: DKFZ, Heidelberg

is Head of the Department Stem Cells and Cancer at the DKFZ and Managing Director of HI-STEM gGmbH. HI-STEM elucidates the molecular and cellular basis for normal and malignant stem cell function and furthermore develops strategies to detect and target cancer and metastasis stem cells.



Christof von Kalle

Institution: NCT and DKFZ, Heidelberg

is Head of the Dept. of Translational Oncology at the NCT and the DKFZ. He chairs the NCT Board of Directors. He is Chair of the comprehensive cancer center network of the German Cancer Aid. His main research fields are stem cell research, mutation analyses and gene transfer.

Speakers



Magnus von Knebel Doeberitz

Institution: DKFZ, Heidelberg

is Head of the Clinical Cooperation Unit Applied Cancer Biology at the DKFZ. Their main interests lie in the detection of oncogenic viruses and in detection of early cancer stages as well as the biology of unstable microsatellites in neoplasia. He founded the biotech company MTM laboratories.



Otmar Wiestler

Institution: DKFZ, Heidelberg

is Chairman of the Management Board and Scientific Director of the DKFZ, thereby leading the largest biomedical research institute in Germany into the 21st century. At the DKFZ, more than 2,500 employees in over 70 divisions and research groups are investigating the basic mechanisms of cancer.



Harald zur Hausen

Institution: DKFZ, Heidelberg

is Nobel Prize laureate in Medicine for his outstanding scientific contributions and identification of papillomaviruses in cervical cancers that led to the development of a vaccine. He was Chairman of the DKFZ from 1983 - 2003. He actively took part in the establishment of the National Center of Tumor Diseases in Heidelberg and was President of the German Cancer Aid Foundation in 2010/11.

Faculty

Abdulla Al Ansari, Doha
Alessandro Bertaccini, Bologna
Gedske Daugaard, Kopenhagen
Maria De Santis, Wien
Michael Droller, New York
Michael Flentje, Würzburg
Norbert Graf, Homburg
Axel Haferkamp, Frankfurt
Oliver Hakenberg, Rostock
Arndt Hartmann, Erlangen
Estrid Hogdall, Kopenhagen
Elke Jäger, Frankfurt
Helmut Klocker, Innsbruck
Glen Kristiansen, Bonn
Stefan Müller, Bonn
Martina Müller-Schilling, Regensburg
Vito Pansadoro, Rom
Jacob Ramon, Tel Aviv
Jens Rassweiler, Heilbronn
Michael Stöckle, Homburg
Levent Türkeri, Istanbul
Wolf Wieland, Regensburg
Bernd Wullich, Erlangen
Martin Zeier, Heidelberg
Xu Zhang, Peking
Christoph Zielinski, Wien

Sponsors and Partners

 abcdruck

 gsk
GlaxoSmithKline

 Roche

 Baxter

 janssen
PHARMACEUTICAL COMPANIES
of Johnson & Johnson

 SIEMENS

 Bayer HealthCare

 MEDCOM
visions. innovations. solutions.

 SONACARE
MEDICAL

 Coloplast

 med
update

 STORZ
KARL STORZ – ENDOSKOPE

 Dendreon
Targeting Cancer, Transforming Lives®

 Metamark
GENETICS, INC.

 Takeda

 ETHICON™
Biosurgery

 NOVARTIS
ONCOLOGY

 TEVA

 FARCO-PHARMA
Im Dienste der Urologie

 Pfizer


 Watson
ELEMENTARY

Transparenz

Die Mitgliedsunternehmen der „Freiwilligen Selbstkontrolle für die Arzneimittelindustrie e.V.“ (FSA) hat zur Schaffung von mehr Transparenz den FSA-Kodex enger gefasst. Zukünftig sind Kongressveranstalter verpflichtet potentielle Teilnehmer von Kongressen bereits im Vorfeld der Veranstaltung über Umfang und Bedingungen der Unterstützung der Arzneimittelindustrie zu informieren. Dieser Verpflichtung kommen wir nach und informieren Sie über die Höhe des Sponsorings der beteiligten Firmen:
Baxter Deutschland GmbH 3.000,00 Euro / Bayer Vital GmbH 5.000,00 Euro / Coloplast GmbH 1.000,00 Euro / GlaxoSmithKline GmbH & Co. KG 8.000,00 Euro / Jansen-Cilag GmbH 10.000,00 Euro / Johnson & Johnson Medical GmbH (ETHICON Biosurgery) 2.000,00 Euro / MedCom GmbH und Watson Medical 4.000,00 Euro / Novartis Pharma GmbH 8.000,00 Euro / Pfizer Pharma GmbH 5.000,00 Euro / Roche Pharma AG 8.000,00 Euro / Siemens AG 4.000,00 Euro / Takeda Pharma Vertrieb GmbH & Co. KG 10.000,00 Euro

Floor Plan

Company	Destination	space sqm	booth no.
Baxter Deutschland GmbH	Unterschleißheim	4	10
Bayer Vital GmbH	Leverkusen	4	12
GlaxoSmithKline GmbH & Co.KG	München	6	5
Jansen-Cilag GmbH	Neuss	6	15
KARL STORZ GmbH & Co. KG	Tuttlingen	6	6
MedCom GmbH	Darmstadt	4	8
Metamark Genetics, Inc.	Cambridge/USA	4	14a/b
Novartis Pharma GmbH	Nürnberg	6	7
Pfizer Pharma GmbH	Berlin	4	13
Watson Elementary	Utrecht/NL	4	8
Roche Pharma AG	Grenzach-Wyhlen	6	4
Siemens AG, Healthcare Sector	Erlangen	4	11
SonaCare Medical	Charlotte/NC/USA	4	13
Takeda Pharma Vertrieb GmbH & Co. KG	Berlin	6	2



high table	●	booth measure 2 x 2 m	■
wardrobe	▬	booth measure 2 x 3m	▬
table and chairs for lunch	▭	booth measure 4 x 1 m	▭

European Foundation for Urology Heidelberg



The medicine of the 21st century is increasingly influenced by socio-political, and particularly economic circumstances, which are leading to an integration of curing and relieving illnesses into the algorithms of market economy financial systems. This development is being intensified not only by the cost explosion in developing and applying new diagnostic and therapeutic techniques, but also by the demographic change of our population structure. Without being expressed this is leading to a questioning of the ethics that have given primacy to the wellbeing of the sick in our collective consciousness for centuries. The young and healthy funders of our society in particular are, not least legitimized by the media influence of political parties, increasingly prepared to accept these perspectives of the “financial feasibility” of health.

The European Foundation for Urology is making a contribution to the retention of “salus aegroti suprema lex” by the voluntary solidarity of its donors towards ill people whose medical treatment would not otherwise be financeable. This target is achieved firstly through direct, earmarked support for patients and secondly, through the individual, selective training of doctors from other national and international institutions. The discipline of urology is particularly suitable for such a project for many reasons. Firstly urology is confronted with illnesses of patients from all age groups, from new-borns to old people, who can very frequently be completely cured by the correct therapy. Examples that can be named include congenital deformities, the consequences of accidents, tumours and organ disorders. Secondly, the discipline of urology is well-organized, manageable and professional, the expertise of which relates not least to intensive national and international collegiality and exchanges of academic experiences.

More on this issue under:

www.efu-heidelberg.de

General Information

Principal organiser

Boris Hadaschik
Sascha Pahernik

CME

Accredited 14 points, category A, by the German LÄK Baden-Württemberg.
Granted 9 European CME credits by the EACCME

Scientific Organisation

Timur Kuru, Thomas Höfner
Department of Urology, UniversityHospital Heidelberg

Congress Organisation

wikonect GmbH | Hagenauer Straße 53 | D-65203 Wiesbaden
Tel.: +49 (0)611 - 20 48 09 21 | Fax: +49 (0)611 - 20 48 09 10
info@wikonect.de | www.wikonect.de

Congress Host

med publico GmbH | Hagenauer Straße 53 | D-65203 Wiesbaden

Location

Communication Center, DKFZ | Im Neuenheimer Feld 280 | 69120 Heidelberg | www.dkfz.de

Patrons of Translations in Urologic Oncology



The congress is supported by
the European Foundation for Urology

